Kiniksa Pharmaceuticals International (NASDAQ: KNSA) is scheduled to release its Q4 2025 earnings results on February 24, 2026, before the market opens. Analysts anticipate the company will report earnings of $0.37 per share and revenue of approximately $200.85 million for the quarter. The earnings call will take place at 8:30 AM ET, providing an opportunity for stakeholders to gain insights into the company’s financial performance.
Stock Performance and Insider Transactions
On Friday, Kiniksa Pharmaceuticals’ stock opened at $47.77. The company has demonstrated notable growth, boasting a market capitalization of $3.62 billion and a price-to-earnings ratio of 106.16. Over the past year, the stock has experienced a low of $18.25 and a high of $47.86, reflecting significant volatility.
Recent insider activity has drawn attention. On February 12, Director Barry D. Quart sold 2,690 shares at an average price of $45.00, totaling $121,050. Following this transaction, Quart’s ownership in the company decreased by 17.66%, leaving him with 12,546 shares valued at approximately $564,570. Additionally, CFO Mark Ragosa sold 17,845 shares on February 9 for an average price of $43.28, equating to about $772,332. This sale represented a 59.62% reduction in Ragosa’s holdings, leaving him with 12,086 shares worth roughly $523,082.
Over the past three months, corporate insiders have sold a total of 123,823 shares, valued at $5.24 million. Corporate insiders currently own 53.48% of Kiniksa’s stock, indicating a significant level of insider involvement.
Analyst Ratings and Market Sentiment
Recent reports from various brokerages have influenced market perceptions of Kiniksa Pharmaceuticals. On January 13, Zacks Research downgraded the company from a “hold” to a “strong sell” rating. In contrast, Canaccord Genuity Group initiated coverage with a “buy” rating and a price target of $62.00. The Goldman Sachs Group similarly raised its target price from $45.00 to $55.00 while maintaining a “buy” rating.
Weiss Ratings reaffirmed a “hold (c)” rating, while Wedbush increased its price target from $48.00 to $50.00 and assigned an “outperform” rating. Currently, seven investment analysts have given Kiniksa a “buy” rating, one has issued a “hold” rating, and one analyst has rated it a “sell.” MarketBeat reports a consensus rating of “Moderate Buy” with a target price set at $53.71.
Kiniksa Pharmaceuticals, founded in 2013 and based in Lexington, Massachusetts, is a biopharmaceutical firm dedicated to developing treatments for patients with immune-mediated diseases. The company focuses on addressing significant unmet medical needs through both marketed drugs and clinical-stage candidates. Its flagship product, Ilaris (canakinumab), targets various inflammatory conditions, showcasing Kiniksa’s commitment to advancing healthcare solutions.
Investors and stakeholders are encouraged to stay informed about Kiniksa Pharmaceuticals as it prepares for its upcoming earnings announcement, which may provide crucial insights into the company’s financial trajectory and market strategy.
